Back to top
more

Defiance Daily Target 2x Long LMND ETF: (LMNX)

(Delayed Data from NASDAQ) As of May 26, 2026 03:56 PM ET

$13.62 USD

13.62
12,913

+0.47 (3.61%)

Volume: 12,913

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

Zacks News

Zacks Equity Research

Why OPKO Health (OPK) Could Be Positioned for a Slump

OPKO Health (OPK) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

    Zacks Equity Research

    Here's Why You Should Add Amedisys (AMED) to Your Portfolio

    Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

      Zacks Equity Research

      Luminex (LMNX) at 52-Week High: What's Driving the Stock?

      Luminex (LMNX) gains from recent FDA approvals and product launches.

        Zacks Equity Research

        Here's Why You Should Invest in Align Technology (ALGN) Now

        Align Technology (ALGN) continues to boost investors' confidence on consistent strength in InvisAlign.

          David Bartosiak headshot

          Five Scorching Hot Strong Buy Stocks

          These five stocks are breaking out to new highs

            Zacks Equity Research

            Medtronic (MDT) Beats on Q2 Earnings, Reiterates FY18 View

            Medtronic (MDT) rides high on strength in major business segments in Q2.

              Zacks Equity Research

              Patterson Companies (PDCO) Misses on Q2 Earnings, Cuts View

              Patterson Companies (PDCO) missed estimates for both the counts in Q2. A downbeat guidance indicates looming concerns.

                Zacks Equity Research

                Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

                Luminex's (LMNX) collaborative agreements with several companies should help expand the adoption of its products.

                  Zacks Equity Research

                  Here's Why Investors Should Buy Myriad Genetics Right Now

                  Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.

                    Zacks Equity Research

                    Myriad Genetics' Latest Alliance to Boost GeneSight Reach

                    Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base